# Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

> **NCT00934180** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Zofran®

## Key facts

- **NCT ID:** NCT00934180
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934180, "Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00934180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*